Phase 2 Trial – Avelumab Plus Regorafenib

Combination treatment with avelumab and regorafenib has shown activity in patients with relapsed/refractory gastrointestinal stromal tumors (GIST), according to research presented at the European Society for Medical Oncology (ESMO) Congress 2023.